Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07471958

Implementation of eHealth Delivery Alternatives for Cancer Genetic Testing for Hereditary Cancer (eREACH3)

The purpose of the study is to understand patient interest in telehealth and digital tools for pre-test genetic education and/or disclosure of genetic test results. Participants will receive telehealth genetic counseling in the home and may be offered various digital tools to help with the counseling and testing process. These are optional and participants can still speak with a genetic counselor if they wish.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Cancer Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Abramson Cancer Center at the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

Location status: Recruiting

Location contact

Angela Bradbury, MD

CONTACT

[email protected]

215-615-3341

About this study

The goal of the eREACH3 Study is to evaluate the implementation of these tools into remote genetic services, evaluating uptake and use of digital tools and outcomes in representative clinical populations. The initial protocol will include two genetic counseling visits, providing comparison outcomes. Future amendments will be provided as digital tools are ready for implementation.

Specific Aim 1: (Reach) Evaluate the uptake, use and acceptability of digital delivery alternatives in remote genetic services provided as alternatives to the traditional two-visit model with a genetic counselor.

Specific Aim 2: (Effectiveness) Evaluate short-term and 6 month patient reported cognitive, affective and behavioral outcomes (2a) with remote genetic services and digital alternatives in representative clinical populations and moderators of outcomes (2b).

Specific Aim 3: (Implementation) Evaluate provider time associated with implementation of remote telehealth services and digital delivery alternatives and barriers and facilitators to future clinical implementation.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years of age or older
  • Speak and understand English
  • Meet current National Comprehensive Cancer Network (NCCN) or other national guidelines for germline genetic testing or are interested in genetic counseling based on personal or family history of cancer. Patients with prior genetic testing are eligible if they meet criteria for updated testing, or if post-test genetic counseling services are requested.

Exclusion criteria

  • Communication difficulties such as:
  • Uncorrected or uncompensated hearing and/or vision impairment. Patients who can successfully use clinical assistance devices are not excluded.
  • Uncorrected or uncompensated speech defects. Patients who can successfully use clinical assistance devices are not excluded.
  • Uncontrolled psychiatric/mental condition or severe physical, neurological or cognitive deficits rendering individual unable to understand study goals and tasks

Treatment and study plan

Primary outcomes

  1. Uptake of Visit 1

    Time frame: Through 6 months

    Participant completion of Visit 1 (yes/no)

  2. Uptake of Digital Visit 1

    Time frame: Through 6 months

    Participant completion of digital intervention as an alternative for Visit 1 (yes/no)

  3. Uptake of genetic testing

    Time frame: Through 6 months

    Participant completion of genetic testing and received results/Visit 2 (yes/no)

Secondary outcomes

  1. The KnowGene Scale

    Time frame: Through study completion, an average of 6 months

    Change in Knowledge - Score Range = 0-16, Higher score = Better outcome

  2. Test result recall

    Time frame: Through study completion, an average of 6 months

    Recall of genetic testing results

  3. Impact of Events Scale (IES)

    Time frame: Through study completion, an average of 6 months

    Change in Cancer Specific Distress - Score Range = 0-40, Lower score = Better outcome

  4. Satisfaction with genetic services

    Time frame: Through study completion, an average of 6 months

    Differences in satisfaction - Score Range = 14-70, Higher score = Better outcome

  5. Multi-dimensional Impact of Cancer Risk Assessment Questionnaire (MICRA)

    Time frame: Through study completion, an average of 6 months

    Change in Uncertainty - Score Range = 0-85, Lower score = Better outcome

  6. Decisional Regret Scale

    Time frame: Through study completion, an average of 6 months

    Differences in decisional regret - Score Range = 5-25, Lower score = Better outcome

Study contacts

Contact information is provided by the study sponsor or research team.

Angela Bradbury, MD

CONTACT

[email protected]

215-615-3341

Kelsey Karpink

CONTACT

[email protected]

215-662-3531

Sponsors and collaborators

Lead sponsor

Abramson Cancer Center at Penn Medicine

Other

Collaborators

  • Fox Chase Cancer Center

Registry information

Acronym: eREACH3

Important dates

Study start
2025
Primary completion
2029
Study completion
2029
First posted
Mar 13, 2026
Registry last updated
Mar 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.